Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 139 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CP Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

NCT02948127
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV LID cp ΔM2-2 Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Jul 22, 2026, 11:02 AM EDT
Completed No phase listed Observational

Pediatric Longitudinal Cohort Study of Chronic Pancreatitis

NCT03672422
View directory record Official record
Conditions
Pancreatitis, Chronic, Pancreatitis, Acute
Interventions
Blood sample, Patient questionnaires, Saliva sample, Urine sample
Diagnostic Test · Behavioral
Lead sponsor
Aliye Uc
Other
Eligibility
0 Years to 17 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
18
States / cities
Beverly Hills, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Jul 22, 2026, 11:02 AM EDT
Terminated No phase listed Observational

An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®

NCT02455024
View directory record Official record
Conditions
Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL
Interventions
Not listed
Lead sponsor
Ariad Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Hackensack, New Jersey • Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children

NCT01021397
View directory record Official record
Conditions
Paramyxoviridae Infections, Virus Diseases
Interventions
rHPIV3cp45, rHPIV3cp45 placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 36 Months
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Not applicable Interventional

Effects of Transcranial Direct Current Stimulation (tDCS) and Motor Learning in Children With Cerebral Palsy (CP)

NCT01852474
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
8 Years to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jul 22, 2026, 11:02 AM EDT
Terminated Phase 4 Interventional Results available

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

NCT01131325
View directory record Official record
Conditions
CML, Philadelphia Chromosome Positive (Ph+), Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels
Interventions
nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Las Vegas, Nevada • Amarillo, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Jul 22, 2026, 11:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Robot-assisted Training in Children With CP

NCT06450158
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Robot (Amadeo)-assisted Training
Device
Lead sponsor
Cook Children's Health Care System
Other
Eligibility
6 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 11:02 AM EDT
Terminated Not applicable Interventional Results available

Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)

NCT00870818
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
Diagnostic Test · Behavioral
Lead sponsor
MacroGenics
Industry
Eligibility
10 Years to 37 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

NCT03106779
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Asciminib, Bosutinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
10
States / cities
Chicago, Illinois • Beech Grove, Indiana • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jul 22, 2026, 11:02 AM EDT
Terminated Not applicable Interventional

FES to Improve Gait in CP

NCT04591288
View directory record Official record
Conditions
Cerebral Palsy, Spastic Diplegia Cerebral Palsy, Gait
Interventions
Functional Electrical Stimulation protocol, Treadmill only protocol
Other
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
10 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Newark, Delaware • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jul 22, 2026, 11:02 AM EDT
Terminated Phase 3 Interventional Results available

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

NCT00519090
View directory record Official record
Conditions
Myelogenous Leukemia
Interventions
Imatinib, Nilotinib (AMN107)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
36
States / cities
Tucson, Arizona • Anaheim, California • Baldwin Park, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Jul 22, 2026, 11:02 AM EDT
Not yet recruiting Not applicable Interventional

Metacognitive Strategy Training Intervention for Transition-Age Youth With Cerebral Palsy

NCT07424079
View directory record Official record
Conditions
Cerebral Palsy (CP)
Interventions
Pathways and Resources for Engagement and Participation, Attention Control Condition
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
13 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 22, 2026, 11:02 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Interventions
Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
13
States / cities
Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 22, 2026, 11:02 AM EDT
No Longer Available No phase listed Expanded access

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy

NCT04029896
View directory record Official record
Conditions
Cerebral Palsy
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
3 Years and older · Male only
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jul 22, 2026, 11:02 AM EDT
Recruiting Phase 2 Interventional

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

NCT06526104
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cirrhosis, Liver
Interventions
Tremelimumab, Durvalumab
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Not applicable Interventional Results available

Constraint-induced Movement Therapy (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegic Cerebral Palsy

NCT00305006
View directory record Official record
Conditions
Cerebral Palsy, Hemiplegia, Children, Pediatric
Interventions
Constraint-Induced Movement Therapy (CIMT), Hand-Arm Bimanual Intensive Therapy (HABIT)
Procedure
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
30 Months to 14 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Development and Evaluation of Computerized Chemosensory Based Orbitofrontal Networks Training for Treatment of Pain

NCT06218407
View directory record Official record
Conditions
Chronic Pain, Low Back Pain
Interventions
Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) short burst paradigm, Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) long burst paradigm, Computerized Chemosensory-Based Orbitofrontal Cortex Training plus beta caryophyllene (CBOT-Plus), Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)
Combination Product
Lead sponsor
Evon Medics LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Jul 22, 2026, 11:02 AM EDT
Not yet recruiting Not applicable Interventional

Evaluating the Bambini Teens Exoskeleton for Pediatric Cerebral Palsy

NCT07146932
View directory record Official record
Conditions
Cerebral Palsy (CP)
Interventions
Pediatric Lower Limb Exoskeleton (Bambini Teens)
Device
Lead sponsor
COSMO ROBOTICS CO., Ltd
Industry
Eligibility
5 Years to 14 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

NCT03578367
View directory record Official record
Conditions
CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
Interventions
Asciminib add-on, Imatinib, Nilotinib, Asciminib 80mg QD (asciminib single agent (ASAC))
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Augusta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy

NCT01147653
View directory record Official record
Conditions
Cerebral Palsy, CP, Spastic Cerebral Palsy
Interventions
Autologous UCB Reinfusion, Placebo
Biological · Other
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
12 Months to 6 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 11:02 AM EDT
Recruiting Not applicable Interventional

WBV and Serial Casting for Children With Cerebral Palsy

NCT06693388
View directory record Official record
Conditions
Cerebral Palsy (CP), Cerebral Palsy
Interventions
Exercise, Whole-Body Vibration, Serial Casting
Other
Lead sponsor
Ben Reader
Other
Eligibility
3 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 22, 2026, 11:02 AM EDT
Not listed Not applicable Interventional

The Feasibility of Telehealth HEP for CP (HEP: Home Exercise Program), (CP: Cerebral Palsy)

NCT04423653
View directory record Official record
Conditions
Cerebral Palsy, Spastic, Telemedicine
Interventions
Telehealth home exercise program
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
11 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Not applicable Interventional Results available

Respiratory Exacerbation Plans for Action and Care Transitions for Children With Severe CP

NCT05292365
View directory record Official record
Conditions
Cerebral Palsy
Interventions
RE-PACT Intervention
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Jul 22, 2026, 11:02 AM EDT
Recruiting Phase 2 Interventional

Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)

NCT06671132
View directory record Official record
Conditions
Chronic Pain, Low Back Pain
Interventions
Computerized Chemosensory-Based Orbitofrontal Cortex Training for Pain, Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)
Combination Product
Lead sponsor
Evon Medics LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Pasadena, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Jul 22, 2026, 11:02 AM EDT